Professor Dame Carol Black, Internationally-Renowned Physician on Connective Tissue Disorders, joins Riptide Bioscience Advisory Board
April 9, 2020
VALLEJO, CA. – Riptide Bioscience, Inc., today announced that Dame Carol M. Black, FRCP, MACP, FMedSci, Foreign Associate Member of the Institute of Medicine USA, renowned clinician/scientist and eminent expert in systemic sclerosis, has joined the company’s Scientific Advisory Board (SAB).
February 13, 2020
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announces the publication in Science Translational Medicine of a seminal article establishing a novel immune checkpoint, potentially useful in the treatment of both cancer and fibrosis.
February 3, 2020
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announces that key results from the application of its antimicrobial drug candidates for inflammatory acne vulgaris infections have been published in the journal Antibiotics, in an article titled “Designed Antimicrobial Peptides for Topical Treatment of Antibiotic Resistant Acne Vulgaris.”
September 1, 2019
SAN FRANCISCO, CA. – Riptide Bioscience, Inc., announces the publication of a research study demonstrating remarkable efficacy for its drug candidate RP557 in recurrent vaginal fungal infections. The study, entitled “Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment,” appears in the August 2019 issue of Antimicrobial Agents and Chemotherapy, a publication of the American Society for Microbiology and the major scholarly journal devoted to antimicrobials (https://aac.asm.org) (doi: 10.1128/AAC.02690-18).
< Additional articles > Next page